Signup to have metrics tracked for this article

By signing up, social media discussions about Corrigendum to "The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma" [Free Radic. Biol. Med. 163 (2021) 141-152]. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Please enter a valid email.
You must agree before submitting.

Example of Metrics tracking for this article:

Layout example
Corrigendum to "The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma" [Free Radic. Biol. Med. 163 (2021) 141-152].
Layout example